Heindl B, Biberthaler P
Klinik für Anaesthesiologie, Klinikum der Ludwig Maximilians Universität, Nussbaumstrasse 20, 80336 München.
Unfallchirurg. 2008 Aug;111(8):574-8, 580-3. doi: 10.1007/s00113-008-1485-x.
Severe intraoperative bleeding may endanger the patient's life, necessitate additional human resources and increase perioperative costs. The aetiology of perioperative coagulopathy is complex and consists of depletion, consumption and dilution of clotting factors and thrombocytes. Cofactors like hypothermia, acidosis and severe anaemia may aggravate coagulopathy. Previously healthy patients often show hypofibrinogenaemia as the primary trigger of coagulopathy, whereas thrombocytopenia rather is a late event during massive bleeding. Early and differentiated diagnosis is essential for initiating targeted therapy. Evaluation of the clinical bleeding situation and coagulation tests, in particular point-of-care testing like thrombelastography, should be used to guide and control the therapeutic strategy. Fresh frozen plasma, concentrates of clotting factors, platelet concentrates and antifibrinolytic drugs are available for therapy of perioperative coagulopathy. To obtain optimal benefit for the patient, these products should be applied based on a therapeutic algorithm.
严重的术中出血可能危及患者生命,需要额外的人力资源,并增加围手术期成本。围手术期凝血病的病因复杂,包括凝血因子和血小板的消耗、损耗及稀释。诸如体温过低、酸中毒和严重贫血等辅助因素可能会加重凝血病。既往健康的患者常表现为低纤维蛋白原血症,这是凝血病的主要触发因素,而血小板减少症则多发生在大出血过程的后期。早期且有针对性的诊断对于启动靶向治疗至关重要。对临床出血情况的评估以及凝血试验,特别是像血栓弹力图这样的即时检测,应用于指导和控制治疗策略。新鲜冰冻血浆、凝血因子浓缩物、血小板浓缩物及抗纤维蛋白溶解药物可用于围手术期凝血病的治疗。为使患者获得最佳疗效,这些产品应基于治疗方案来应用。